Journal Publications

Expand All

2020

2019


Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2018


• Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE,


2017


2017.


Chapman JA, Sgroi DC, Goss PE, Zarella E, Binns S, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Badovinac-Crnjevic T, Shepherd LE, Pollak MN. Relapse-free


• Jiang S, Chen B, Tu D. Inference on treatment-covariate interaction based on a nonparametric measure of treatment effects and censored survival data. Statist Med n/a, 2016.


- Regan MM, Francis PA, Pagani O, Fleming GF, Walley BA, Viale G, Colleoni M, Láng I,


2015


- Bernstein OA, Campbell J, Rajan DK, Kachura JR, Simons ME, Beecroft JR, Jaskolka JD, Ringash J, Ho CS, Tan KT. Randomized Trial Comparing Radiologic Pigtail


Lin NU, Lee EQ, Aoyama H, Barani IJ, Barbioriak DP, Baumert BG, Bendzus M, Brown
Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Thibault I, Chang EL, Sheehan J, Ahluwalia MS, Guckenberger M, Sohn M-J, Ryu S,


Litère S, de Vries EGE, Seymour L, Sargent D, Shankar L, Bogaerts J. The components


- Ringash J. Facing head and neck cancer deaths head on: Lessons for survival. Cancer
120: 1446-9, 2014.


- Robinson AG, Booth CM, Eisenhauer EA. Progression-free survival as an end-point in solid tumours - Perspectives from clinical trials and clinical practice. Eur J Can 50: 2303-8, 2014.


2013


- Chapman JA, Nielsen T, Ellis M, Bernard P, Chia S, Gelmon K, Pritchard K, Maitre A,
Goss P, Leung S, Shepherd L, Bramwell V. Effect of continuous statistically
standardized measures of estrogen and progesterone receptors on disease-free survival

  RG, O'Connell MJ, Sargent DJ. Innovative estimation of survival compared to standard
  using Adjuvant Colon Cancer Endpoints (ACCENT) database. Br J Cancer 108: 784-90,
  2013.

  2013.

- de Almeida JR, Witterick IJ, Gullane PJ, Gentili F, Lohfeld L, Ringash J, Thoma A,
  Vescan AD. Quality of life instruments for skull base pathology: Systematic review and

- Dent SF, Gelmon KA, Chi KN, Jonker DJ, Wainman N, Capier CA, Chen EX, Lyons JF,
  Seymour L. NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour

  I, Tu D, Stanton HA, Booth CM, Meyer RM. Treatment Success in Cancer: Industry
  Compared to Publicly Sponsored Randomized Controlled Trials. PLoS ONE 8: e58711,
  2013.

- Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD,
  Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT,
  Kahl BS, Horning SJ. The efficacy and tolerability of adriamycin, bleomycin, vinblastine,
  dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive
  analysis from the North American intergroup trial E2496. Br J Haematol 161: 76-86,
  2013.

- Freeman GA, Kimmelman J, Dancey J, Monzon JG. Reporting practices of
  pharmacodynamic studies involving invasive research procedures in cancer trials. Br J

- Friboulet L, Olaussen KA, Pignon J-P, Shepherd FA, Tsao M-S, Graziano S, Kratzke R,
  Douillard J-Y, Seymour L, Pirker R, Filipits M, André F, Solary E, Ponsonnailles F, Robin
  Chevalier T, Dunant A, Rousseau V, Le Teuff G, Brambilla E, Soria J-C. ERCC1 Isoform
  Expression and DNA Repair in Non-Small-Cell Lung Cancer. N Engl J Med 368:
  1101-10, 2013.

- Goodwin RA, Jamal R, Tu D, Walsh W, Dancey J, Oza AM, Elit L, Eisenhauer EA.
  Clinical and toxicity predictors of response and progression to temsirolimus in women

- Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff
  PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA,
  Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized Phase III Trial of
  ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and
  Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern

- Goss GD, O'Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, Edelman MJ,
  Lilenbaum R, Choy H, Khuri F, Pisters K, Gandara D, Kernstine K, Butts C, Noble J,
  Hensing TA, Rowland K, Schiller J, Ding K, Shepherd FA. Gefitinib Versus Placebo in
  Completely Resected Non-Small-Cell Lung Cancer: Results of the NCIC CTG BR19

- Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Ansari RH,


- Jamal R, Goodwin RA, Tu D, Walsh W, Lacombe D, Eisenhauer EA. Performance of


• Sgroi DC, Carney E, Zarrilla E, Steffel L, Binns SN, Finkelstein DM, Szymanik J, Bhan AK, Shepherd LE, Zhang Y, Schnabel CA, Erlander MG, Ingle JN, Porter P, Muss HB,


- de Souza JA, Davis DW, Zhang Y, Khattri A, Seiwert TY, Aktolga S, Wong SJ, Kozloff


Jiang S, Tu D. Inference on the probability as a measurement of treatment effect under a density ratio model and random censoring. Computational Statistics and Data Analysis 56: 1069-78, 2012.


2012.


2011


- O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman D, Bramwell VH, Andrusis IL, Pritchard KI. Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Res Treat 128: 401-9, 2011.


Sargent D, Shi Q, Yothers G, Van CE, Cassidy J, Saltz L, Wolmark N, Bot B, Grothey A, Buyse M, de GA. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 47: 990-6, 2011.


- Mackay HJ, Gallinger S, Tsao MS, McLachlin CM, Tu D, Keiser K, Eisenhauer EA, Oza AM. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: Results from studies of the NCIC Clinical Trials Group (NCIC CTG). Eur J Can 46: 1365-73, 2010


- Miller NA, Chapman J-AW, Qian J, Christens-Barry WA, Fu Y, Yuan Y, Lickley LA, Axelrod DE. Heterogeneity between ducts of the same nuclear grade involved by duct


- Tan X, Takahara G, Tu D. Optimal two-stage design for the phase II cancer clinical trials


2009


- Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD,


- Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, Leighl NB, Shepherd FA,


2008

- Chan JA, Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J,


• Lee CW, Belanger K, Rao SC, Petrella TM, Tozer RG, Wood L, Savage KJ, Eisenhauer EA, Synold TW, Wainman N, Seymour L. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of


2007


• Laurie SA, Ding K, Whitehead M, Feld R, Murray N, Shepherd FA, Seymour L. The


- Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields ALA, Mayer RJ. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus


2006


- Hirte H, Vergote IB, Jeffrey JR, Grimshaw RN, Coppieters S, Schwartz B, Tu D, Sadura


2006.

Tong FK, Chow S, Hedley D. Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. Cytometry B Clin Cytom 70: 107-14, 2006.


- Vermorken JB, Avall-Lundqvist E, Pfisterer J, Bacon M, On behalf of the GCIG representing AGO-OVAR ANZGOG EORTC-GCG GEICO GINECO GOG JGOG MRC


2004


2003


Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton


2000


1999


• Hoskins PJ, Eisenhauer EA, van Glabbeke M, Vermorken JB, Tu D, James K. Predicting outcome after initial relapse of epithelial ovarian cancer: can we identify patients who will not benefit from further therapy? CME J Gynecol Oncol Chapter 13 Part 1: 64-8, 1999.


Osoba D. What has been learned from measuring health-related quality of life in clinical oncology. Eur J Can 35: 1565-70, 1999.


1997


• Osoba D, Aaronson N, Zee B, teVelde A, Sprangers M. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. Quality of Life Research 6: 103-8, 1997.
• Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell V, Wierzbicki


---

1996


- Dent S, Eisenhauer E. Phase I trial design: are new methodologies being put into practice? Ann Oncol 7: 561-6, 1996.


- Forsyth P, Cairncross G, Stewart D, Goodyear M, Wainman N, Eisenhauer E. Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National


- Tu D, Gross AJ. A Bartlett type correction for the subject-years method in comparing


1995

- Latrelle J, Stewart D, Laberge F, Hoskins P, Rusthoven J, McMurtrie E, Warr D, Yelle L,


1994


- Eisenhauer E, Lippman S, Kavanagh J, Parades-Espinoza M, Arnold A, Hong W,


1993


• Niezgoda H, Pater J. A validation study of the domains of the core EORTC quality of life


1992

Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1991

1990


1989

- Bramwell V, Quirt I, Warr D, Verma S, Young V, Knowling M, Eisenhauer E. Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. A Canadian Sarcoma-NCI Canada Clinical Trials Group
Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1988


1987

- McCulloch P, Eisenhauer E, Shibata H, Young V. Phase II study of intravenous


1986


1985


1984


1980


1979